tag:blogger.com,1999:blog-16774010.post8925918499949295552..comments2024-01-25T17:58:34.297-05:00Comments on Scott's Web Log: Exubera Manufacturer Cuts Jobs Due to Poor SalesScott Shttp://www.blogger.com/profile/03286529314567223617noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-16774010.post-47894171286040495532007-07-10T11:49:00.000-04:002007-07-10T11:49:00.000-04:00Scott - where did I read about coke? Please help m...Scott - where did I read about coke? Please help me here. I am getting hysterical. TRULY! Pls read by last blog entry/comment!Chrissie in Belgiumhttps://www.blogger.com/profile/02556806942193998413noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-51371302475751185752007-07-07T23:45:00.000-04:002007-07-07T23:45:00.000-04:00Scott, I spoke with 2 sales reps - one was Rene wh...Scott, I spoke with 2 sales reps - one was Rene who was excellent and I can't remember the other persons name - I'll forward you their info from my office on Monday.Wingmanhttps://www.blogger.com/profile/00867789638868481704noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-80626862777484634312007-07-05T12:26:00.000-04:002007-07-05T12:26:00.000-04:00The fact is that the type 1 market is simply not l...The fact is that the type 1 market is simply not large enough to attract the interest of big pharma, which is fixated not on profitable niche products, but on blockbusters that sell more than $1 billion per year.<BR/><BR/>I agree with your thoughts on strategy, but frankly, our thoughts really don't matter to the executives running these companies, only visions of blockbusters seem do. Luckily, Wall Street has grown very tired of this business model, and the stocks for most of the big pharmaceutical companies have languished over the past 3 years. Given the lackluster drug pipelines, they should not expect their shares to do much better anytime soon. Its time for new management!Scott Shttps://www.blogger.com/profile/03286529314567223617noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-27870351466243662802007-07-05T11:53:00.000-04:002007-07-05T11:53:00.000-04:00There was always the question of Pulmonary problem...There was always the question of Pulmonary problems associated with Inhaled Insulin, which also contributed to their problems.<BR/>The fact that Eli lilly and Novo Nordisk want to get involved in Inhaled Insulin us a mistake. They should put their R&D $$ to making C-peptide injectables available instead.<BR/>There is more of a profitable market available for the manufacture of C-peptide or anything else that will target Diabetes-related Complications. This is where the focus should be put, rather than the delivery of Insulin!!!!!<BR/>The gauge on injectable needles (31) are so thin so as to afford virtually "pain-free" injections to anyone. In addition the Insulin Analogues provide very fast absorption rates, so again the advantage to the Pulmonary site becomes meaningless as far as immediate action.BetterCellhttps://www.blogger.com/profile/13667917240368089110noreply@blogger.com